Suppr超能文献

引言与提供药物流产服务:两国的故事,技术有其必要性但并不充分。

Introduction and provision of medical abortion: a tale of two countries in which technology is necessary but not sufficient.

机构信息

Gynuity Health Projects, New York, NY 10010, USA.

出版信息

Contraception. 2011 Apr;83(4):322-9. doi: 10.1016/j.contraception.2010.08.009.

Abstract

INTRODUCTION

Medical abortion is one of the most important advances of the last century in the field of reproductive health. However, the introduction and use of the technology varies widely among countries.

STUDY DESIGN

The article examines the commercial, political, regulatory, and legislative history of the introduction of mifepristone-misoprostol in France and the United States.

RESULTS

While the introduction of the technology has been deemed a "success" in each country, existing patterns of medical research, abortion service provision and health care financing came to alter the uptake and use of medical abortion in the two countries.

CONCLUSION

Proof of safety, efficacy and patient acceptability are in themselves not enough to assure successful introduction and widespread use of medical innovations. However, the case studies illustrate that there is more than one way to arrive at expansion of new technologies.

摘要

简介

药物流产是上个世纪生殖健康领域最重要的进步之一。然而,这项技术在各国的引进和使用情况存在很大差异。

研究设计

本文考察了米非司酮-米索前列醇在法国和美国的引进的商业、政治、监管和立法历史。

结果

虽然该技术在这两个国家都被认为是“成功”的,但现有的医学研究、堕胎服务提供和医疗保健融资模式改变了这两个国家对药物流产的接受和使用。

结论

安全性、有效性和患者可接受性的证据本身并不能保证医疗创新的成功引进和广泛应用。然而,这些案例研究表明,新技术的扩展并非只有一种途径。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验